Price$5.51+1.83 (+49.73%)
2026-03-052026-06-08
News · 26 weeks45+114%
2025-12-142026-06-07
Mix3090d
- Insider14(47%)
- Other8(27%)
- SEC Filings8(27%)
Latest news
25 items- SECEdesa Biotech Inc. filed SEC Form 8-K: Other Events8-K - Edesa Biotech, Inc. (0001540159) (Filer)
- PREdesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney InjuryAnalyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also experiencing respiratory distressNew data and analysis to be presented today at the 63rd European Renal Association Congress TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress. The data, which expand upon previously reported Phase 3
- INSIDERChief Executive Officer Nijhawan Pardeep was granted 1,671 shares, increasing direct ownership by 0.23% to 731,134 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERDirector Marshall Patrick was granted 19,000 shares, increasing direct ownership by 36% to 71,666 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERDirector Macdonald Sean Arthur was granted 19,000 shares, increasing direct ownership by 86% to 41,054 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERDirector Chypyha Joan was granted 19,000 shares, increasing direct ownership by 172% to 30,029 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERChief Financial Officer Weiler Peter J. was granted 64,609 shares, increasing direct ownership by 99% to 129,609 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERPresident Brooks Michael J was granted 64,609 shares, increasing direct ownership by 28% to 291,479 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERDirector Sistilli Carlo was granted 19,000 shares, increasing direct ownership by 62% to 49,417 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERDirector Olson Charles V was granted 19,000 shares, increasing direct ownership by 173% to 30,000 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERChief Executive Officer Nijhawan Pardeep was granted 96,913 shares, increasing direct ownership by 15% to 729,463 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERDirector Liu Da David was granted 19,000 shares, increasing direct ownership by 345% to 24,501 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- SECSEC Form S-8 filed by Edesa Biotech Inc.S-8 - Edesa Biotech, Inc. (0001540159) (Filer)
- SECEdesa Biotech Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Edesa Biotech, Inc. (0001540159) (Filer)
- PREdesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology ConferenceOral presentation at ERA Congress, the flagship European nephrology meetingCompany expects to present additional data TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it will present data on paridiprubart, its first-in-class anti-TLR4 antibody, at the 63rd European Renal Association (ERA) Congress, to be held June 3 – 6, 2026, in Glasgow, Scotland. The ERA Congress is one of the world's leading nephrology meetings, convening clinicians and researchers focused on kidney disease. Edesa's accepted oral presentation will feature
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Edesa Biotech Inc.SCHEDULE 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Edesa Biotech Inc.SCHEDULE 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)
- SECEdesa Biotech Inc. filed SEC Form 8-K: Leadership Update8-K - Edesa Biotech, Inc. (0001540159) (Filer)
- SECSEC Form 10-Q filed by Edesa Biotech Inc.10-Q - Edesa Biotech, Inc. (0001540159) (Filer)
- SECEdesa Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Edesa Biotech, Inc. (0001540159) (Filer)
- PREdesa Biotech Reports Fiscal 2nd Quarter 2026 ResultsTORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2026 and provided an update on its business. During the second quarter, Edesa continued preparations for an upcoming Phase 2 clinical study of its drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), in moderate-to-severe nonsegmental vitiligo patients. The company reported that it has contracted a clinical research organization and initiated outreach to potential clinical sites and investigators. Based on
- INSIDERChief Executive Officer Nijhawan Pardeep was granted 1,159 shares, increasing direct ownership by 0.18% to 632,550 units (SEC Form 4)4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- INSIDERSEC Form 4 filed by Nijhawan Pardeep4 - Edesa Biotech, Inc. (0001540159) (Issuer)
- SECSEC Form DEFA14A filed by Edesa Biotech Inc.DEFA14A - Edesa Biotech, Inc. (0001540159) (Filer)
- SECSEC Form DEF 14A filed by Edesa Biotech Inc.DEF 14A - Edesa Biotech, Inc. (0001540159) (Filer)
EDSA FAQ
6 questionsWhat does Edesa Biotech Inc. do?
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an...Where does EDSA stock trade?
Edesa Biotech Inc. (EDSA) is listed on NASDAQ.What sector and industry is EDSA in?
Edesa Biotech Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about EDSA?
Edesa Biotech Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $1600.00 price target on 2021-12-20. Recent price targets cluster around $1600.00.What companies are similar to EDSA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare EDSA side-by-side with any of them on Quantisnow.How can I track EDSA on Quantisnow?
Quantisnow aggregates Edesa Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EDSA to receive live email and push alerts on every new disclosure.